CTXR - Citius Pharmaceuticals

Discussion in 'Stock Message Boards NYSE, NASDAQ, AMEX' started by Dan Thunderbolt, May 15, 2020.

  1. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    730
    Likes Received:
    77
    Citius Pharmaceuticals Announces $76.5 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
    February 17, 2021
    CRANFORD, N.J., Feb. 17, 2021 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) ("Citius" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing critical care drug products, today announced that it has entered into definitive agreements with certain healthcare-focused and institutional investors for the purchase of an aggregate of 50,830,566 shares of its common stock and accompanying warrants to purchase up to an aggregate of 25,415,283 shares of its common stock, at a purchase price of $1.505 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to take place on or about February 19, 2021, subject to the satisfaction of customary closing conditions.

    https://ir.citiuspharma.com/press-r...maceuticals-announces-76-5-million-registered
     
  2. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    730
    Likes Received:
    77
    Now above $2 :thumbsup:

    Crazy high volume. Citius will do very well imo leading up to their Phase 3 Mino-Lok product decision early April to possibly end the the trial early because the results are so powerful...
     
    T0rm3nted likes this.
  3. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    730
    Likes Received:
    77
    https://dawsonjames.com/wp-content/uploads/2021/02/CTXR.2.18.21.pdf

    February 18, 2021

    BUY: Funded All the Way Through Commercialization
    Citius raises “big cash” –an additional $75 million, which follows a previous raise of $20 million in January. We had anticipated dilution in our model, but with this raise,we now see the company as funded all the way through the commercialization of Mino-Lok. Given the strength of the balance sheet, we actually see lower corporate risk. Adding in the new shares, removing our projected future raises, and adjusting our risk from 30% to 15% but leaving our probability of success for Mino-Lok at 70%, and adjusting the commercial timing out to 2022 (from 2021) culminates in our price target actually adjusting higher from $6.00 to $8.00.
     
  4. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    730
    Likes Received:
    77
    CTXR: A Blockbuster Pharma Still Under The Radar
    Feb. 20, 2021 11:31 AM ET|About: Citius Pharmaceuticals, Inc. (CTXR)
    Summary
    Recent offerings provide enough funding through commercialization.

    Mino-Lok will have no competetion.

    IDMC changes interim data review from 75% to 65%.

    Phase 3 data "very soon"

    Price Target $8.

    https://seekingalpha.com/instablog/...969-ctxr-blockbuster-pharma-still-under-radar

    Investment Thesis
    Citius Pharmaceuticals (Ticker: $CTXR) is only a couple months away from anticipated positive Phase 3 results for its lead product Mino-Lok. However, with its $2 share price, it has a modest ~$250M market cap. If the results are positive, this small biotech share price will quickly rise to $8, or higher, as the market starts to realize its potential.
     
  5. Dan Thunderbolt

    Dan Thunderbolt Active Member

    Joined:
    Aug 26, 2017
    Messages:
    730
    Likes Received:
    77
    Citius Pharma Makes Calculated Market Moves with Phase 3 Results Looming for Potential Blockbuster Product - GeneOnline News
    2021-02-21

    Among the three products that Citius is developing, Mino-Lok has achieved the most milestones and is currently undergoing Phase 3 evaluations. It has already received the Qualified Infectious Disease Product (“QIDP”) designation providing fast track status, priority review, and additional market exclusivity. If approved, Citius believes that Mino-Lok could enter a $1.5 billion worth market and prove to be a blockbuster without any immediate competition.

    It is currently being evaluated in a Phase 3 trial to evaluate the safety and efficacy in combination with systemic antibiotics in the treatment of CRBSIs. In a letter to shareholders, Citius said that it expects to receive an interim analysis of the pivotal trial and review by the Data Monitoring Committee (DMC) in the second quarter of this year. Once positive results are confirmed, Citius is expected to quickly push for FDA clearance and manufacturing.

    https://geneonline.news/en/citius-p...ts-looming-for-potential-blockbuster-product/
     

Share This Page